Ewing sarcoma is the second most frequent bone tumour of childhood and adolescence that
can also arise in soft tissue. Ewing sarcoma is a highly aggressive cancer, with a survival of …

Findings over the past decade have identified aberrant activation of the ETS transcription
factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene …

Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in the NAD
salvage pathway of mammalian cells and is overexpressed in numerous types of cancers …

Targeting of PARP enzymes has emerged as an effective therapeutic strategy to selectively
target cancer cells with deficiencies in homologous recombination signaling. Currently used …

Many cancer types are driven by oncogenic transcription factors that have been difficult to
drug. Transcriptional inhibitors, however, may offer inroads into targeting these cancers …

Abstract Trabectedin (Yondelis®, ET-743) is a marine-derived natural product that was
initially isolated from the marine ascidian Ecteinascidia turbinata and is currently prepared …

Purpose: Novel targeted therapeutics have transformed the care of subsets of patients with
cancer. In pediatric malignancies, however, with simple tumor genomes and infrequent …

Standard therapy of osteosarcoma (OS) and Ewing sarcoma (EW) rests on cytotoxic
regimes, which are largely unsuccessful in advanced patients. Preclinical models are …

Ewing sarcoma is a pediatric cancer driven by EWS-ETS transcription factor fusion
oncoproteins in an otherwise stable genomic background. The majority of tumors express …

Background Soft‐tissue sarcomas (STS) describe a heterogeneous group of mesenchymal
tumors with limited treatment options. Targeted therapies exist for BRCA1/2 gene alterations …